Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma

Toni K. Choueiri, Robert J. Motzer, Jose A. Karam, Wesley Yip, Cristina Suárez, Dingwei Ye, Zhisong He, Christian Caglevic, Tom Ferguson, Yen-Hwa Chang, Carlos Rojas, Roberto Iacovelli, Yüksel Ürün, Elena Verzoni, Juan Carlos Vázquez Limón, Camillo Porta, Robert G. Uzzo, Jae Lyun Lee, Balaji Venugopal, Rana R. McKay, Hans Hammers, Hideaki Miyake, Jad Chahoud, Hong Liu, Joseph E. Burgents, Manish Sharma, Thomas B. Powles

Open source

DOI: 10.1056/nejmoa2518245
Published: 2026-07-02
Container: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa2518245,
  title = {Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma},
  author = {Toni K. Choueiri and Robert J. Motzer and Jose A. Karam and Wesley Yip and Cristina Suárez and Dingwei Ye and Zhisong He and Christian Caglevic and Tom Ferguson and Yen-Hwa Chang and Carlos Rojas and Roberto Iacovelli and Yüksel Ürün and Elena Verzoni and Juan Carlos Vázquez Limón and Camillo Porta and Robert G. Uzzo and Jae Lyun Lee and Balaji Venugopal and Rana R. McKay and Hans Hammers and Hideaki Miyake and Jad Chahoud and Hong Liu and Joseph E. Burgents and Manish Sharma and Thomas B. Powles},
  year = {2026},
  journal = {New England Journal of Medicine},
  doi = {10.1056/nejmoa2518245},
  url = {https://doi.org/10.1056/nejmoa2518245}
}

RIS

TY  - JOUR
TI  - Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma
AU  - Toni K. Choueiri
AU  - Robert J. Motzer
AU  - Jose A. Karam
AU  - Wesley Yip
AU  - Cristina Suárez
AU  - Dingwei Ye
AU  - Zhisong He
AU  - Christian Caglevic
AU  - Tom Ferguson
AU  - Yen-Hwa Chang
AU  - Carlos Rojas
AU  - Roberto Iacovelli
AU  - Yüksel Ürün
AU  - Elena Verzoni
AU  - Juan Carlos Vázquez Limón
AU  - Camillo Porta
AU  - Robert G. Uzzo
AU  - Jae Lyun Lee
AU  - Balaji Venugopal
AU  - Rana R. McKay
AU  - Hans Hammers
AU  - Hideaki Miyake
AU  - Jad Chahoud
AU  - Hong Liu
AU  - Joseph E. Burgents
AU  - Manish Sharma
AU  - Thomas B. Powles
PY  - 2026
JO  - New England Journal of Medicine
DO  - 10.1056/nejmoa2518245
UR  - https://doi.org/10.1056/nejmoa2518245
ER  -

APA

Choueiri, T. K., Motzer, R. J., Karam, J. A., Yip, W., Suárez, C., Ye, D., He, Z., Caglevic, C., Ferguson, T., Chang, Y., Rojas, C., Iacovelli, R., Ürün, Y., Verzoni, E., Limón, J. C. V., Porta, C., Uzzo, R. G., Lee, J. L., Venugopal, B., McKay, R. R., Hammers, H., Miyake, H., Chahoud, J., Liu, H., Burgents, J. E., Sharma, M., & Powles, T. B. (2026). Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2518245

Source records

crossref · retrieved 2026-09-27T09:37:29.729Z